PCN reports : psychiatry and clinical neurosciences最新文献_第6页

CAT-Hokkaido: A tablet-based assessment of cognitive impairment in schizophrenia. 北海道：基于片剂的精神分裂症认知障碍评估。

IF 1.3

PCN reports : psychiatry and clinical neurosciences Pub Date : 2026-04-29 eCollection Date: 2026-06-01 DOI: 10.1002/pcn5.70339

Atsuhito Toyomaki, Hayato Watanabe, Ryo Sawagashira, Chiemi Kubota, Naoki Hashimoto, Takahiro A Kato

{"title":"CAT-Hokkaido: A tablet-based assessment of cognitive impairment in schizophrenia.","authors":"Atsuhito Toyomaki, Hayato Watanabe, Ryo Sawagashira, Chiemi Kubota, Naoki Hashimoto, Takahiro A Kato","doi":"10.1002/pcn5.70339","DOIUrl":"10.1002/pcn5.70339","url":null,"abstract":"Aim: Cognitive impairment is a core feature of schizophrenia and is typically assessed using paper-and-pencil neuropsychological batteries. However, these traditional methods are time-consuming and place a substantial burden on examiners before, during, and after administration. To address this issue, we developed CAT-Hokkaido, a brief tablet-based cognitive assessment tool designed to assess multiple neurocognitive domains while reducing examiner burden.Methods: We assessed its validity in a sample of 50 individuals with schizophrenia and 50 healthy controls, using the MATRICS Consensus Cognitive Battery (MCCB) as a reference standard. Group differences in CAT-Hokkaido and MCCB scores were analyzed.Results: CAT-Hokkaido identified significant performance deficits in four out of six tasks among patients with schizophrenia. These four tests evaluated processing speed, executive function, sustained attention, and verbal learning. Additionally, all tasks demonstrated significant correlations with their corresponding MCCB measures, supporting the tool's convergent validity.Conclusion: These findings suggest that CAT-Hokkaido may serve as a surrogate tool for assessing cognitive impairment in schizophrenia.","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"5 ","pages":"e70339"},"PeriodicalIF":1.3,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13125948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The importance of longitudinal evaluation using DAT-SPECT in organophosphate-induced toxic parkinsonism. 在有机磷诱导的中毒性帕金森病中应用pet纵向评价的重要性。

IF 1.3

PCN reports : psychiatry and clinical neurosciences Pub Date : 2026-04-29 eCollection Date: 2026-06-01 DOI: 10.1002/pcn5.70333

Shuhei Nakao, Yoichiro Kogoh, Hideki Funahashi, Yusei Yanoma, Minako Azuma, Yasushi Ishida, Yoji Hirano

{"title":"The importance of longitudinal evaluation using DAT-SPECT in organophosphate-induced toxic parkinsonism.","authors":"Shuhei Nakao, Yoichiro Kogoh, Hideki Funahashi, Yusei Yanoma, Minako Azuma, Yasushi Ishida, Yoji Hirano","doi":"10.1002/pcn5.70333","DOIUrl":"10.1002/pcn5.70333","url":null,"abstract":"Background: Clinicians encounter considerable challenges in the diagnosis and treatment of organophosphate-induced toxic parkinsonism following acute poisoning. Here, we report the importance of longitudinal evaluation of a patient with organophosphate-induced toxic parkinsonism using dopamine transporter single-photon emission computed tomography (DAT-SPECT). This case may provide crucial insights into the pathophysiology of the syndrome and inform therapeutic decision-making.Case presentation: We report a case of organophosphate-induced toxic parkinsonism with persistent parkinsonian symptoms evaluated longitudinally using DAT-SPECT. A 68-year-old woman with a history of bipolar disorder was found collapsed at home on Day 0 with impaired consciousness, miosis, hypersalivation, and bradycardia. Organophosphate poisoning was diagnosed based on markedly reduced cholinesterase levels and the presence of an organophosphate pesticide in a shed at her home. Parkinsonian symptoms gradually emerged from Day 18, including hypophonia and a gait disturbance. On Day 60, DAT-SPECT showed reduced radiotracer uptake in the bilateral striatum, more pronounced on the right. After toxic parkinsonism was diagnosed, l-dopa was titrated up to 600 mg/day without clinical benefit and discontinued due to adverse effects. Treatment with amantadine and trihexyphenidyl was then initiated, resulting in partial symptomatic improvement, although symptoms persisted. Despite clinical improvement, follow-up DAT-SPECT on Day 131 showed a further reduction in striatal tracer uptake, whereas quantitative improvement was observed on Day 200.Conclusion: Parkinsonism is an uncommon sequela of organophosphate poisoning and may be accompanied by abnormal DAT-SPECT findings. Moreover, amantadine and trihexyphenidyl may represent effective therapeutic options for this condition.","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"5 2","pages":"e70333"},"PeriodicalIF":1.3,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13129215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Brivaracetam-associated manic episode in a patient with bipolar disorder: A case report. 双相情感障碍患者布伐西坦相关躁狂发作1例报告

IF 1.3

PCN reports : psychiatry and clinical neurosciences Pub Date : 2026-04-27 eCollection Date: 2026-06-01 DOI: 10.1002/pcn5.70335

Mihoko Kawai, Jun Miyata, Kousuke Kanemoto

{"title":"Brivaracetam-associated manic episode in a patient with bipolar disorder: A case report.","authors":"Mihoko Kawai, Jun Miyata, Kousuke Kanemoto","doi":"10.1002/pcn5.70335","DOIUrl":"10.1002/pcn5.70335","url":null,"abstract":"Background: Levetiracetam and brivaracetam (BRV) are antiseizure medications that exert effects by binding to synaptic vesicle protein 2A (SV2A). BRV exhibits higher affinity and selectivity for SV2A and is generally considered to have a favorable psychiatric tolerability profile. However, reports on serious psychiatric adverse events remain scarce.Case presentation: We herein report a 60-year-old man with a history of bipolar disorder who had remained psychiatrically stable for many years under aripiprazole treatment. He was diagnosed with focal epilepsy based on stereotyped focal seizures with impaired awareness and right temporal epileptiform discharges observed on electroencephalography. BRV was initiated at a dose of 50 mg/day and later increased to 100 mg/day. Several weeks after initiation, he developed elevated mood, marked irritability, emotional dysregulation, and delusion-like ideation, progressing to a manic episode with psychotic features requiring inpatient psychiatric care. BRV was discontinued and replaced with lacosamide, coupled with intensification of a mood-stabilizing treatment, which resulted in the gradual resolution of manic symptoms. No epileptic seizures occurred during BRV treatment or after the medication switch.Conclusion: This case suggests that, despite its generally favorable psychiatric tolerability, BRV may be associated with the emergence of symptoms in patients with bipolar disorder. These findings highlight the importance of careful psychiatric risk assessment and close monitoring when initiating BRV in individuals with underlying mood vulnerability.","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"5 2","pages":"e70335"},"PeriodicalIF":1.3,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13112175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147791512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dihydroxy fatty acids can be used for screening autism traits in toddlers. 二羟基脂肪酸可以用来筛选幼儿的自闭症特征。

IF 1.3

PCN reports : psychiatry and clinical neurosciences Pub Date : 2026-04-20 eCollection Date: 2026-06-01 DOI: 10.1002/pcn5.70338

Takaharu Hirai, Naoko Umeda, Takayo Ohto-Nakanishi, Toru Fujioka, Keisuke Wakusawa, Takahiro Nara, Kenji J Tsuchiya, Hideo Matsuzaki

引用次数: 0

ADHD medications and drug withdrawal: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. ADHD药物和药物戒断：一项使用FDA不良事件报告系统（FAERS）数据库的药物警戒研究。

IF 1.3

PCN reports : psychiatry and clinical neurosciences Pub Date : 2026-04-20 eCollection Date: 2026-06-01 DOI: 10.1002/pcn5.70337

Takumi Ebina, Kunihiro Iwamoto, Masashi Ikeda

引用次数: 0

Clinical dilemma of mood stabilizer augmentation in treatment-resistant schizophrenia with residual phase: A case report of valproate-associated hypoglycemia and cytopenia, and subsequent lithium response. 残存期难治性精神分裂症心境稳定剂增强的临床困境：丙戊酸盐相关低血糖和细胞减少症病例报告，以及随后的锂反应

IF 1.3

PCN reports : psychiatry and clinical neurosciences Pub Date : 2026-04-17 eCollection Date: 2026-06-01 DOI: 10.1002/pcn5.70334

Yoshiki Kasagi, Naomichi Okamoto, Reiji Yoshimura

{"title":"Clinical dilemma of mood stabilizer augmentation in treatment-resistant schizophrenia with residual phase: A case report of valproate-associated hypoglycemia and cytopenia, and subsequent lithium response.","authors":"Yoshiki Kasagi, Naomichi Okamoto, Reiji Yoshimura","doi":"10.1002/pcn5.70334","DOIUrl":"10.1002/pcn5.70334","url":null,"abstract":"Background: Mood stabilizer augmentation is frequently used in treatment-resistant schizophrenia despite limited guideline recommendations. Evidence for its efficacy and safety in the residual phase, however, remains insufficient.Case presentation: A 49-year-old Japanese woman with treatment-resistant residual schizophrenia exhibited persistent agitation and aggression despite antipsychotic therapy. Valproate augmentation (800 mg/day) improved irritability and psychomotor agitation but was complicated by hypoglycemia, suggestive of relative carnitine deficiency, and subsequent pancytopenia. Both adverse events resolved after discontinuation. Behavioral symptoms markedly worsened following withdrawal. Clozapine and electroconvulsive therapy were declined. Lithium augmentation (600 mg/day; serum level 0.8 mEq/L) was initiated, resulting in improvement of dangerous behaviors and agitation. The Brief Psychiatric Rating Scale total score improved from 80 to 64, particularly in the hostility and excitement items. No readmission to the psychiatric ward occurred during a 3-month follow-up.Conclusion: This case highlights the clinical dilemma of mood stabilizer augmentation in residual-phase schizophrenia. While valproate demonstrated behavioral efficacy, serious adverse events necessitated its discontinuation. Lithium may represent a potential alternative for managing aggression and agitation, but further research is warranted.","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"5 2","pages":"e70334"},"PeriodicalIF":1.3,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13087732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147725048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preliminary real-world trends in outpatient revenue following implementation of disease-modifying therapies in general hospital psychiatry in Japan. 日本综合医院精神病学实施疾病改善疗法后门诊收入的初步现实趋势。

IF 1.3

PCN reports : psychiatry and clinical neurosciences Pub Date : 2026-04-13 eCollection Date: 2026-06-01 DOI: 10.1002/pcn5.70328

Kyohei Otani, Hiroyuki Ishihara, Tetsu Nakamura, Kana Kawabe

引用次数: 0

Pediatric catatonia: A case report and review of the management. 小儿紧张症：1例报告及治疗回顾。

IF 1.3

PCN reports : psychiatry and clinical neurosciences Pub Date : 2026-04-12 eCollection Date: 2026-06-01 DOI: 10.1002/pcn5.70329

Alison Thornton, Russell Birkett

{"title":"Pediatric catatonia: A case report and review of the management.","authors":"Alison Thornton, Russell Birkett","doi":"10.1002/pcn5.70329","DOIUrl":"10.1002/pcn5.70329","url":null,"abstract":"Background: Catatonia is when someone does not respond to stimuli or their environment whilst awake. Catatonia can present in a variety of ways, including a change in movement, speech, and behavior. There is limited research on the causes and management of catatonia in an adult population and even more so in the pediatric population.Case presentation: A 13-year-old presented with a 2-week sudden onset history of distress and preoccupation regarding a child being in danger. Over the next few weeks, he was represented on multiple occasions and had a rapid weight loss due to refusing oral intake. He displayed increasing preoccupations and was admitted for intravenous fluids and commenced on nasogastric feeds. He declined rapidly, presenting with symptoms of catatonia, including stupor, catalepsy, mutism, and posturing. Physical health causes for this presentation were ruled out with imaging and bloods completed, and he was trialled on lorazepam. He responded well to the lorazepam, and after 5 days, the nasogastric tube was removed, and he commenced eating, drinking, communicating, and mobilizing. The lorazepam was reduced, and his symptoms reemerged. The lorazepam was titrated back up and reduced again at a slower rate.Conclusion: Whilst managing this case, it was noted that there is a lack of guidance available for catatonia in both adult and pediatric populations. There is particularly a lack of guidance on how to titrate onto and off lorazepam. This case highlighted a need for further research to support the development of guidelines for the management of pediatric catatonia.","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"5 2","pages":"e70329"},"PeriodicalIF":1.3,"publicationDate":"2026-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13071320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147694040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of 2-4 mg brexpiprazole in the management of schizophrenia: A systematic review and meta-analysis. 2-4 mg brexpiprazole治疗精神分裂症的疗效和安全性：一项系统回顾和荟萃分析。

IF 1.3

PCN reports : psychiatry and clinical neurosciences Pub Date : 2026-04-12 eCollection Date: 2026-06-01 DOI: 10.1002/pcn5.70332

Sher Bano, Aashan Ahmad, Abdul Haseeb Mohammed, Ismailova Rushana Nurbekovna, Saja Saad, Noor Fatima, Muhammad Bilal Akbar, Zainab Salahuddin, Sadikun Nabi, Mohammad Mustafa Ababneh, Laiba Ajmal, Sidra Hariss, Hiba Manaf, Farah Saleh, Raouf Khan

{"title":"Efficacy and safety of 2-4 mg brexpiprazole in the management of schizophrenia: A systematic review and meta-analysis.","authors":"Sher Bano, Aashan Ahmad, Abdul Haseeb Mohammed, Ismailova Rushana Nurbekovna, Saja Saad, Noor Fatima, Muhammad Bilal Akbar, Zainab Salahuddin, Sadikun Nabi, Mohammad Mustafa Ababneh, Laiba Ajmal, Sidra Hariss, Hiba Manaf, Farah Saleh, Raouf Khan","doi":"10.1002/pcn5.70332","DOIUrl":"10.1002/pcn5.70332","url":null,"abstract":"Brexpiprazole 2-4 mg daily is a novel dopamine D2 partial agonist approved for schizophrenia and improves effectiveness and tolerance by balancing D2, 5-HT1A, and 5-HT2A effects. This review assesses current evidence on its efficacy and safety within this dose range. PubMed, ScienceDirect, and The Cochrane Library were searched for trials published between 2011 and 2025 using specific keywords. Eligibility criteria included schizophrenia patients diagnosed using DSM-IV, DSM-IV-TR, DSM-5, or ICD-10, with intervention being 2-4 mg of brexpiprazole. Positive and Negative Syndrome Scale (PANSS) score and Clinical Global Impression - Severity scale (CGI-S) were the primary efficacy endpoints, and treatment-related adverse events were used to assess efficacy. Subgroup analysis was planned between the two dosage groups. The quality of randomized controlled trials (RCTs) was evaluated using the ROB2 tool, and the protocol registration was completed in PROSPERO. Among 464 retrieved articles, five trials with 2182 participants were found to be eligible. Brexpiprazole significantly improved total PANSS scores (mean difference [MD] -5.76; 95% confidence interval [CI] -7.69 to -3.83; p < 0.00001), positive subscale scores, negative subscale scores, and CGI-S scores (MD -1.35; 95% CI -1.87 to -0.84; p < 0.00001). The treatment-emergent adverse events were similar to placebo, and the risk of discontinuation was less with brexpiprazole (risk ratio 0.58; 95% CI 0.430.77; p = 0.0002). The most usual extrapyramidal symptom was akathisia. Brexpiprazole 2-4 mg showed significant improvements in PANSS and CGI-S scores, with a lower risk of treatment discontinuation. These findings support its efficacy and tolerability in managing schizophrenia.","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"5 2","pages":"e70332"},"PeriodicalIF":1.3,"publicationDate":"2026-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13071367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147694083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between anticipated follow-up duration and treatment outcomes in anorexia nervosa: Insights from a Japanese medical prison. 神经性厌食症预期随访时间与治疗结果之间的关系：来自日本医疗监狱的见解

IF 1.3

PCN reports : psychiatry and clinical neurosciences Pub Date : 2026-04-07 eCollection Date: 2026-06-01 DOI: 10.1002/pcn5.70331

Wataru Nakagawa, Etsuko Miyamoto, Atsumi Tonai, Marika Okamura, Yusuke Okumura, Takayuki Okada

{"title":"Association between anticipated follow-up duration and treatment outcomes in anorexia nervosa: Insights from a Japanese medical prison.","authors":"Wataru Nakagawa, Etsuko Miyamoto, Atsumi Tonai, Marika Okamura, Yusuke Okumura, Takayuki Okada","doi":"10.1002/pcn5.70331","DOIUrl":"10.1002/pcn5.70331","url":null,"abstract":"Aim: Recovery rates in eating disorders generally improve with longer follow-up periods. However, the effect of a longer follow-up period itself on prognosis remains unclear due to high dropout rates. This study examined whether treatment outcomes in anorexia nervosa are influenced by the anticipated follow-up duration, using a unique cohort from a Japanese medical prison, where follow-up periods are predetermined by sentence length.Methods: Data from 149 patients diagnosed with anorexia nervosa were analyzed. Logistic and Cox regression analyses were performed to identify predictors of favorable outcomes, defined as sufficient clinical improvement to allow transfer back to the original correctional facility.Results: Longer remaining sentence length, representing an anticipated follow-up duration, was associated with favorable outcomes (p < 0.001), independent of the actual hospitalization duration. Higher body mass index at admission and a lifetime diagnosis of an eating disorder also predicted favorable outcomes. Factors previously associated with treatment dropout, such as low educational attainment and adverse childhood experiences, were not predictive of outcomes.Conclusion: Longer remaining sentence length was associated with favorable treatment outcomes. Although this variable was conceptualized as a proxy for anticipated follow-up duration, physicians' expectations were not directly assessed. Therefore, the findings should be interpreted as observational and hypothesis-generating rather than causal. Future research is needed to determine whether physicians' expectations regarding anticipated follow-up duration influence treatment processes and outcomes.","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"5 2","pages":"e70331"},"PeriodicalIF":1.3,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13058227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147647644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0